Safety Shot, Inc. has received comments from the United States Securities and Exchange Commission (SEC) regarding its Post-Effective Amendment No. 6 on Form S-1, which was filed on February 5, 2024. The SEC's limited review has led to requests for additional information and clarification on several points. The SEC has asked Safety Shot to revise their disclosure concerning allegations made by Bigger Capital Fund, L.P., and to clarify claims related to their products NoStingz and SS-100. Specifically, the SEC is seeking further information on how SS-100 would be characterized as a drug and its potential qualification for Orphan Drug Designation for treating Acute Alcohol Poisoning. Safety Shot is also required to clarify the FDA approval process for drugs and the process for obtaining Orphan Drug Designation. The SEC has reminded the company of its responsibility for the accuracy of disclosures and has provided contact information for further questions. Safety Shot must respond by filing a post-effective amendment with the requested information.

Safety Shot, Inc. has received comments from the United States Securities and Exchange Commission (SEC) regarding its Post-Effective Amendment No. 6 on Form S-1, which was filed on February 5, 2024. The SEC's limited review has led to requests for additional information and clarification on several points. The SEC has asked Safety Shot to revise their disclosure concerning allegations made by Bigger Capital Fund, L.P., and to clarify claims related to their products NoStingz and SS-100. Specifically, the SEC is seeking further information on how SS-100 would be characterized as a drug and its potential qualification for Orphan Drug Designation for treating Acute Alcohol Poisoning. Safety Shot is also required to clarify the FDA approval process for drugs and the process for obtaining Orphan Drug Designation. The SEC has reminded the company of its responsibility for the accuracy of disclosures and has provided contact information for further questions. Safety Shot must respond by filing a post-effective amendment with the requested information.